查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2133913

個人化醫療與藥物基因體學市場預測至2034年－按產品、技術、應用、最終用戶和地區分類的全球分析

Personalized Medicine & Pharmacogenomics Market Forecasts to 2034 - Global Analysis By Product, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球個人化醫療和藥物基因體學市場預計將在 2026 年達到 6,641 億美元，在預測期內以 12.0% 的複合年成長率成長，到 2034 年達到 1,6443 億美元。

個人化醫療和藥物基因體學使醫療專業人員能夠根據患者的基因資訊、生物學特徵以及特定疾病的特徵來客製化治療方案。藥物基因組學分析可以顯示基因差異如何影響藥物反應（療效、劑量需求、副作用等）。基因測序、分子診斷、標靶治療和精準醫療的進步正在加速其應用。將基因組分析的見解與臨床實踐相結合，能夠幫助醫生做出更明智的治療決策，改善治療效果，最大限度地減少藥物相關併發症，促進以患者為中心的護理，並支持更高效、更個性化的醫療管理。

根據美國食品藥物管理局(FDA) 的說法，藥物附加檔中包含的藥物藥物基因體學資訊範例包括阿巴卡韋的 HLA-B、Clopidogrel的 CYP2C19、可待因的 CYP2D6、Fluorouracil的 DPYD 以及依來沙替尼/依巴替尼/替扎沙替尼的 CFTR，這表明基因標誌物與藥物相關的藥物指導物與生物相關的 CFTR，實際上被用於確定基因標記與藥物相關的藥物。

基因組檢測的廣泛應用

基因組檢測的日益普及正在加速個人化醫療和藥物基因體學市場的成長，因為它能夠幫助醫生做出更精準的醫療決策。基因定序和分子診斷技術的進步提高了檢測的可及性、可靠性和臨床價值。醫生可以利用基因資訊來評估疾病風險、識別相關生物標記並選擇更合適的治療方案。藥物基因組學評估也能深入了解個體對藥物的反應，有助於減少藥物相關併發症並最佳化治療方案的選擇。臨床應用的不斷拓展和檢測技術的進步將繼續推動個人化醫療的發展。

基因組檢測和個人化醫療高成本

基因組定序和個人化醫療的高昂成本可能會阻礙個人化醫療和藥物基因體學市場的擴張。基因定序、專業診斷程序和藥物基因體學評估可能需要先進的實驗室設施、訓練有素的專業人員和尖端技術，從而推高實施成本。有限的醫療預算可能會使某些醫療服務提供者和患者群體難以獲得這些服務。此外，標靶治療和重複的診斷評估會進一步增加治療成本。這些經濟挑戰可能會阻礙個人化醫療解決方案的普及，並妨礙其在整個醫療系統中的廣泛應用。

基因組藥物發現的擴展

基因組資訊在藥物研發中的日益廣泛應用，為個人化醫療和藥物基因體學市場帶來了巨大的成長機會。製藥和生物技術公司可以利用基因數據來識別疾病標靶、發現預測性生物標記物，並開發針對特定患者群體的治療方案。整合基因組資訊可以提高患者選擇的準確性，並有助於進行更具針對性的臨床研究。醫療機構、研究機構、科技公司和製藥公司之間的合作能夠加速創新。這個不斷擴展的生態系統將促進個人化療法的開發，並加強藥物基因組學的應用。

快速的技術進步和互通性挑戰

快速的技術發展和醫療系統整合的挑戰對個人化醫療和藥物基因體學市場構成潛在威脅。定序技術、診斷平台、軟體和臨床基礎設施的不斷變化使得系統相容性難以保證。基因組資料格式的差異以及檢查室、基因組資料庫和電子健康記錄（EHR）之間連接不足，會阻礙資訊的無縫共用。此外，醫療機構可能面臨持續的技術升級和整合成本。這些障礙可能導致技術應用延遲和工作流程中斷，從而限制個人化醫療技術的實際效益。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為個人化醫療和藥物基因體學市場帶來了挑戰和機會。常規醫療服務的中斷影響了特定的基因檢測、研究和醫療活動。同時，疫情也凸顯了基因組資訊在評估疾病進展、治療反應和藥物-基因交互作用的重要性。對新冠患者的研究表明，基於藥物基因組學的治療決策具有潛在的應用價值。此外，疫情期間建立的基因組資料集和病患生物檢體資料庫也成為推動精準醫療和支持預防性藥物基因體學檢測進一步普及的寶貴資源。

在預測期內，藥物基因體學檢測套組細分市場預計將佔據最大的市場佔有率。

在預測期內，藥物基因體學檢測套組盒預計將佔據最大的市場佔有率，因為它們提供標準化的工具來檢測影響個別藥物反應的基因變異。這些試劑盒能夠識別與藥物代謝、療效和潛在副作用相關的關鍵基因變異。它們在醫院、診斷檢查室、研究機構和臨床環境中的效用，鞏固了該領域在藥物基因體學工作流程中的作用。檢測技術的進步、多重測量能力、測試準確性和方便用戶使用型介面的改進，正在推動其進一步普及，並支持在個人化治療方案製定中更廣泛地應用基因資訊。

預計在預測期內，罕見疾病和遺傳疾病領域將呈現最高的複合年成長率。

在預測期內，罕見疾病和遺傳疾病領域預計將呈現最高的成長率。對罕見疾病相關遺傳機制的深入了解正在推動基因組檢測、先進診斷技術和個人化治療方案的應用。藥物基因體學工具正在幫助檢測具有臨床意義的遺傳變異，並指導選擇合適的治療方案。定序、生物標記鑑定、標靶治療和分子診斷技術的持續進步正在拓展個人化醫療的作用，促進臨床醫生和研究人員在應對遺傳性和複雜罕見疾病方面更多地採用這些技術。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健體系、完善的基因組基礎設施以及精準醫療的廣泛應用。定序平台、基因檢測、分子診斷和個人化療法的普及，正在推動該地區的市場擴張。大型製藥公司、生技公司和學術機構的存在，以及有利的法規環境，也促進了這些技術的普及應用。特別是美國，憑藉其先進的醫療設施、廣泛的研究活動以及藥物基因組學資訊在臨床治療和決策中日益成長的應用，對北美的市場主導地位做出了重大貢獻。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療體系的現代化和精準醫療的日益普及。基因組檢測基礎設施、診斷能力和研究活動的不斷完善，為市場發展創造了有利條件。慢性病負擔的加重和醫療成本的不斷攀升，推動了對個人化醫療的需求。政府的支持、製藥業的參與以及醫療機構與技術提供者之間的夥伴關係，也促進了藥物基因組學檢測和個人化醫療方法在亞太地區的廣泛應用。

免費客製化服務：

所有購買此報告的客戶均可從以下免費自訂選項中選擇一項：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 主要國家的市場估算和預測，以及根據客戶需求量身定做的複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球個人化醫療和藥物基因體學市場：按產品分類

  • 藥物基因體學檢測套組
  • 基因定序平台
  • 伴隨診斷
  • 個人化治療
  • 臨床決策支援工具
  • 生物資訊學和數據分析解決方案

第6章：全球個人化醫療和藥物基因體學市場：按技術分類

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 微陣列分析
  • 質譜分析
  • CRISPR和基因編輯工具

第7章：全球個人化醫療和藥物基因體學市場：按應用分類

  • 腫瘤學
  • 心血管疾病
  • 神經病變
  • 感染疾病
  • 罕見疾病和遺傳疾病

第8章：全球個人化醫療和藥物基因體學市場：按最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 研究和學術機構
  • 製藥和生物技術公司

第9章：全球個人化醫療和藥物基因體學市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • F. Hoffmann-La Roche Ltd.（Roche）
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc
  • Pfizer Inc.
  • Novartis
  • Myriad Genetics, Inc.
  • Foundation Medicine
  • Guardant Health
  • Quest Diagnostics
  • Labcorp
  • Tempus AI, Inc.
  • 23andMe
  • Vertex Pharmaceuticals
  • Bristol-Myers Squibb
  • BioMarin Pharmaceutical
  • CSL Behring
  • Kite Pharma
  • Janssen Biotech
Product Code: SMRC39633

According to Stratistics MRC, the Global Personalized Medicine & Pharmacogenomics Market is accounted for $664.1 billion in 2026 and is expected to reach $1644.3 billion by 2034 growing at a CAGR of 12.0% during the forecast period. Personalized Medicine & Pharmacogenomics enables healthcare providers to customize treatments based on patients' genetic information, biological traits, and specific disease characteristics. Pharmacogenomic analysis can reveal how genetic differences affect responses to medicines, including effectiveness, dosage requirements, and adverse reactions. Developments in genomic sequencing, molecular diagnostics, targeted therapies, and precision healthcare are accelerating adoption. Combining genomic insights with clinical practices allows physicians to make more informed treatment decisions, improve therapeutic effectiveness, minimize medication-related complications, and promote patient-focused care while supporting more efficient and individualized healthcare management.

According to the U.S. FDA, examples of pharmacogenomic information in drug labeling include HLA-B for abacavir, CYP2C19 for clopidogrel, CYP2D6 for codeine, DPYD for fluorouracil, and CFTR for elexacaftor/ivacaftor/tezacaftor, demonstrating the practical use of genetic biomarkers in guiding medication-related decisions.

Market Dynamics:

Driver:

Growing adoption of genomic testing

Increasing use of genomic testing is accelerating the Personalized Medicine & Pharmacogenomics Market by enabling more precise healthcare decisions. Technological progress in genetic sequencing and molecular diagnostics has improved the accessibility, reliability, and clinical value of testing. Physicians can use genetic information to assess disease risks, recognize relevant biomarkers, and select therapies more appropriately. Pharmacogenomic assessments also provide insights into individual drug responses, helping reduce medication-related complications and improve treatment selection. Broader clinical adoption and advancing testing technologies continue to encourage personalized healthcare implementation.

Restraint:

High cost of genomic testing and personalized therapies

Expensive genomic analysis and individualized treatment can hinder expansion of the Personalized Medicine & Pharmacogenomics Market. Genetic sequencing, specialized diagnostic procedures, and pharmacogenomic evaluations may require advanced laboratory facilities, trained professionals, and sophisticated technologies, increasing implementation expenses. Limited healthcare funding can make these services difficult to access for certain providers and patient populations. Furthermore, targeted medications and repeated diagnostic assessments can add to treatment costs. These economic challenges can discourage adoption and prevent personalized healthcare solutions from achieving broader utilization across healthcare systems.

Opportunity:

Expansion of genomic-based drug development

Increasing use of genomic information in drug development creates substantial growth opportunities for the Personalized Medicine & Pharmacogenomics Market. Pharmaceutical and biotechnology organizations can apply genetic data to identify disease targets, discover predictive biomarkers, and develop therapies designed for particular patient groups. Incorporating genomic insights may improve patient selection and contribute to more focused clinical research. Collaboration among healthcare providers, research institutions, technology companies, and pharmaceutical organizations can accelerate innovation. This expanding ecosystem can encourage development of personalized treatments and strengthen pharmacogenomic applications.

Threat:

Rapid technological evolution and interoperability challenges

Fast-paced technological development and difficulties integrating healthcare systems pose potential threats to the Personalized Medicine & Pharmacogenomics Market. Continuous changes in sequencing technologies, diagnostic platforms, software, and clinical infrastructure can make system compatibility challenging. Differences in genomic data formats and inadequate connectivity among laboratories, genomic databases, and electronic health records may hinder seamless information sharing. Healthcare organizations can also encounter recurring expenses related to technology upgrades and integration. Such barriers may delay adoption, disrupt workflows, and limit the practical benefits of personalized healthcare technologies.

Covid-19 Impact:

The COVID-19 pandemic produced both challenges and opportunities for the Personalized Medicine & Pharmacogenomics Market. Disruptions to routine medical services affected certain genetic testing, research, and healthcare activities. At the same time, the crisis highlighted the importance of genomic information for evaluating disease progression, therapeutic responses, and drug-gene interactions. Research involving COVID-19 patients demonstrated potential applications for pharmacogenomic-guided treatment decisions. Additionally, genomic datasets and patient biorepositories established during the pandemic created valuable resources for advancing precision medicine and supporting greater adoption of preemptive pharmacogenomic testing.

The pharmacogenomic testing kits segment is expected to be the largest during the forecast period

The pharmacogenomic testing kits segment is expected to account for the largest market share during the forecast period by offering standardized tools for detecting genetic variations that influence how individuals respond to medicines. They enable identification of important gene variants linked with drug metabolism, therapeutic effectiveness, and potential adverse reactions. Their usefulness across hospitals, diagnostic laboratories, research organizations, and clinical environments strengthens their role in pharmacogenomic workflows. Advancements in assay technologies, multiplex capabilities, testing accuracy, and user-friendly formats are further encouraging adoption, supporting broader use of genetic information in individualized treatment planning.

The rare & genetic disorders segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the rare & genetic disorders segment is predicted to witness the highest growth rate. Greater understanding of genetic mechanisms associated with uncommon diseases is driving the use of genomic testing, precision diagnostics, and customized treatment approaches. Pharmacogenomic tools can assist in detecting clinically relevant genetic variations and guiding appropriate therapeutic choices. Continued progress in sequencing, biomarker identification, targeted medicines, and molecular diagnostics is broadening the role of personalized healthcare, encouraging increased adoption among clinicians and researchers managing inherited and complex rare diseases.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its sophisticated healthcare systems, developed genomics infrastructure, and widespread implementation of precision medicine. High availability of sequencing platforms, genetic testing, molecular diagnostics, and personalized therapies supports regional expansion. The presence of major pharmaceutical companies, biotechnology firms, academic institutions, and favorable regulatory conditions also strengthens adoption. The United States particularly contributes to North American dominance through advanced healthcare facilities, extensive research activity, and growing incorporation of pharmacogenomic information into clinical treatment and decision-making.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare systems modernize and precision medicine adoption expands. Improvements in genomic testing infrastructure, diagnostic capabilities, and research activities are creating favorable conditions for market development. Increasing chronic disease burdens and rising healthcare spending are encouraging demand for individualized therapies. Government support, pharmaceutical industry participation, and partnerships among healthcare institutions and technology providers are additionally promoting wider implementation of pharmacogenomic testing and personalized treatment approaches throughout Asia Pacific.

Key players in the market

Some of the key players in Personalized Medicine & Pharmacogenomics Market include F. Hoffmann-La Roche Ltd. (Roche), Illumina, Inc., Thermo Fisher Scientific Inc, Pfizer Inc., Novartis, Myriad Genetics, Inc., Foundation Medicine, Guardant Health, Quest Diagnostics, Labcorp, Tempus AI, Inc., 23andMe, Vertex Pharmaceuticals, Bristol-Myers Squibb, BioMarin Pharmaceutical, CSL Behring, Kite Pharma and Janssen Biotech.

Key Developments:

In December 2025, Pfizer Inc. announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.

In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.

In May 2025, Novartis has signed a strategic agreement with Shanghai Pharma to help sell the Swiss company's mature ophthalmic products in China. Novartis will leverage Shanghai Pharma's omni-channel integrated marketing services and broad market coverage capabilities to accelerate the reach of some Novartis drugs for ocular infections and glaucoma in smaller territories not currently targeted by Novartis.

Products Covered:

  • Pharmacogenomic Testing Kits
  • Genetic Sequencing Platforms
  • Companion Diagnostics
  • Personalized Therapeutics
  • Clinical Decision Support Tools
  • Bioinformatics & Data Analytics Solutions

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray Analysis
  • Mass Spectrometry
  • CRISPR & Gene Editing Tools

Applications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Rare & Genetic Disorders

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Pharmaceutical & Biotechnology Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Medicine & Pharmacogenomics Market, By Product

  • 5.1 Pharmacogenomic Testing Kits
  • 5.2 Genetic Sequencing Platforms
  • 5.3 Companion Diagnostics
  • 5.4 Personalized Therapeutics
  • 5.5 Clinical Decision Support Tools
  • 5.6 Bioinformatics & Data Analytics Solutions

6 Global Personalized Medicine & Pharmacogenomics Market, By Technology

  • 6.1 Next-Generation Sequencing (NGS)
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Microarray Analysis
  • 6.4 Mass Spectrometry
  • 6.5 CRISPR & Gene Editing Tools

7 Global Personalized Medicine & Pharmacogenomics Market, By Application

  • 7.1 Oncology
  • 7.2 Cardiovascular Diseases
  • 7.3 Neurological Disorders
  • 7.4 Infectious Diseases
  • 7.5 Rare & Genetic Disorders

8 Global Personalized Medicine & Pharmacogenomics Market, By End User

  • 8.1 Hospitals & Clinics
  • 8.2 Diagnostic Laboratories
  • 8.3 Research & Academic Institutes
  • 8.4 Pharmaceutical & Biotechnology Companies

9 Global Personalized Medicine & Pharmacogenomics Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd. (Roche)
  • 12.2 Illumina, Inc.
  • 12.3 Thermo Fisher Scientific Inc
  • 12.4 Pfizer Inc.
  • 12.5 Novartis
  • 12.6 Myriad Genetics, Inc.
  • 12.7 Foundation Medicine
  • 12.8 Guardant Health
  • 12.9 Quest Diagnostics
  • 12.10 Labcorp
  • 12.11 Tempus AI, Inc.
  • 12.12 23andMe
  • 12.13 Vertex Pharmaceuticals
  • 12.14 Bristol-Myers Squibb
  • 12.15 BioMarin Pharmaceutical
  • 12.16 CSL Behring
  • 12.17 Kite Pharma
  • 12.18 Janssen Biotech

List of Tables

  • Table 1 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Pharmacogenomic Testing Kits (2023-2034) ($MN)
  • Table 4 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Genetic Sequencing Platforms (2023-2034) ($MN)
  • Table 5 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Companion Diagnostics (2023-2034) ($MN)
  • Table 6 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Personalized Therapeutics (2023-2034) ($MN)
  • Table 7 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Clinical Decision Support Tools (2023-2034) ($MN)
  • Table 8 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Bioinformatics & Data Analytics Solutions (2023-2034) ($MN)
  • Table 9 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 10 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 11 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 12 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Microarray Analysis (2023-2034) ($MN)
  • Table 13 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Mass Spectrometry (2023-2034) ($MN)
  • Table 14 Global Personalized Medicine & Pharmacogenomics Market Outlook, By CRISPR & Gene Editing Tools (2023-2034) ($MN)
  • Table 15 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Application (2023-2034) ($MN)
  • Table 16 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 17 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 18 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 19 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 20 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Rare & Genetic Disorders (2023-2034) ($MN)
  • Table 21 Global Personalized Medicine & Pharmacogenomics Market Outlook, By End User (2023-2034) ($MN)
  • Table 22 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 23 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 24 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 25 Global Personalized Medicine & Pharmacogenomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.